12 completed, 4 terminated, 1 active not recruiting, 1 unknown. 18 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 12, Terminated 4, Active not recruiting 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow MK 2206: new trials by email Literature Review of MK 2206 trials Research Report on MK 2206
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Akt Inhibitor MK2206, Dinaciclib, Laboratory Biomarker Analysis - Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2013-01-15 | 2017-08-22 |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate - Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 60 | 2012-09-01 | 2013-09-30 |
| Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Akt Inhibitor MK2206, Hydroxychloroquine - Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2011-11-23 | 2026-09-09 |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Akt Inhibitor MK2206, Bendamustine Hydrochloride, Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2011-09-01 | 2017-09-15 |
| MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer Akt Inhibitor MK2206, Anastrozole, Fulvestrant - Estrogen Receptor Positive, Invasive Breast Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 31 | 2011-04-21 | 2018-07-23 |
| MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies MK-2206, Paclitaxel, Trastuzumab - Advanced Solid Tumors, Tumors | Phase 1 | Completed | University of California, San Francisco | 17 | 2011-03-01 | 2014-04-17 |
| Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) ridaforolimus, MK-0752, MK-2206 - Advanced Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 65 | 2011-02-01 | 2015-08-27 |
| MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Paclitaxel - Adult Solid Neoplasm, Recurrent Breast Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2011-01-05 | 2017-08-25 |
| Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1 | Terminated | National Cancer Institute (NCI) | 4 | 2011-01-01 | 2015-08-27 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) dalotuzumab, MK-0752, ridaforolimus - Neoplasms Malignant | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 47 | 2010-11-22 | 2018-08-16 |
| Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer Akt inhibitor MK2206, lapatinib ditosylate, pharmacological study - HER2-positive Breast Cancer, Male Breast Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 28 | 2010-11-01 | 2014-10-23 |
| Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC) MK2206 - Non Small Cell Lung Cancer | Phase 1 | Unknown | National Taiwan University Hospital | 21 | 2010-09-01 | 2013-05-03 |
| A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007) MK2206 every other day, MK2206 once weekly - Solid Tumors | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2010-02-01 | 2015-09-07 |
| A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) MK-2206, AZD6244 - Locally Advanced or Metastatic Solid Tumors | Phase 1 | Completed | Merck Sharp & Dohme LLC | 63 | 2009-11-23 | 2018-08-07 |
| A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) MK-2206, Trastuzumab, Lapatinib - Advanced Solid Tumors, Breast Cancer | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 33 | 2009-09-15 | 2024-06-04 |
| A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) MK-2206, docetaxel, erlotinib - Locally Advanced, Metastatic Solid Tumors | Phase 1 | Completed | Merck Sharp & Dohme LLC | 77 | 2009-03-17 | 2019-11-12 |
| Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) MK-2206 - Locally Advanced Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Merck Sharp & Dohme LLC | 104 | 2008-04-15 | 2019-04-01 |
Breast Neoplasms (7) · Neoplasms (4) · Breast Neoplasms, Male (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Ovarian Neoplasms (2) · Blast Crisis (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1)
National Cancer Institute (NCI) (9) · Merck Sharp & Dohme LLC (7) · National Taiwan University Hospital (1) · University of California, San Francisco (1)
United States (10) · Canada (2) · Taiwan (1)
Amye Tevaarwerk (1) · Chih-Hsin Yang, MD, Ph.D (1) · Cynthia Ma (1) · Devika Gajria (1) · Funda Meric-Bernstam (1) · Jo Chien, MD (1) · Jyoti Malhotra (1) · Maryam Fouladi (1) · Nilofer Azad (1) · Patricia LoRusso (1) · Wei Ding (1)
PMID 22025163, PMID 24252402, PMID 24387695, PMID 25239610, PMID 25290091, PMID 25516890, PMID 25931518
U01CA062490 (2), UM1CA186716 (2), 2009 (1), N01CM00099 (1), P30CA006973 (1), P30CA008748 (1), P30CA014520 (1), P30CA016672 (1), P30CA022453 (1), P30CA072720 (1), P30CA091842 (1), R21CA172997 (1), U01CA062461 (1), U01CA062487 (1), U01CA062491 (1)